Intercept Pharmaceuticals (NASDAQ:ICPT) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.57) by ($0.86), Bloomberg Earnings reports. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $39.01 million. During the same quarter last year, the business earned ($4.84) earnings per share. Intercept Pharmaceuticals’s revenue was up 173.1% compared to the same quarter last year.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $2.61 during midday trading on Thursday, hitting $56.02. The stock had a trading volume of 1,447,000 shares, compared to its average volume of 1,107,216. The company has a market capitalization of $1,490.00, a P/E ratio of -4.24 and a beta of -2.13. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.
ICPT has been the subject of a number of research analyst reports. Wedbush reiterated a “buy” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Deutsche Bank initiated coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 target price for the company. Goldman Sachs Group downgraded Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a report on Wednesday, November 1st. Five equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and a consensus target price of $132.14.
TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/14/intercept-pharmaceuticals-icpt-releases-earnings-results-misses-expectations-by-1-04-eps.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.